Podlesak Dennis's Form 4 filing
Syndax Pharmaceuticals IncSNDX · filed Aug 18, 2025
- Accession no.
- 0000950170-25-109815
- Filed
- Aug 18, 2025
- Trade date
- Aug 14-18, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market sales total $874.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Podlesak DennisCIK 0001314595 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 14, 2025 | Common Stock | MOption exerciseAcquired | +19,200 | $7.20 | +$138,240 | 210,963 | Direct | |
| Aug 14, 2025 | Common Stock | SSaleDisposed | −19,200 | $14.19F2 | −$272,448 | 191,763 | Direct | |
| Aug 15, 2025 | Common Stock | MOption exerciseAcquired | +19,200 | $7.20 | +$138,240 | 210,963 | Direct | |
| Aug 15, 2025 | Common Stock | SSaleDisposed | −19,200 | $15.54F3 | −$298,368 | 191,763 | Direct | |
| Aug 18, 2025 | Common Stock | MOption exerciseAcquired | +19,200 | $7.20 | +$138,240 | 210,963 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −19,200 | $15.84F4 | −$304,128 | 191,763 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 14, 2025 | Common Stock | MOption exerciseDisposed | −19,200 | $0.00 | $0 | 0 | Direct | |
| Aug 15, 2025 | Common Stock | MOption exerciseDisposed | −14,400 | $0.00 | $0 | 0 | Direct | |
| Aug 15, 2025 | Common Stock | MOption exerciseDisposed | −4,800 | $0.00 | $0 | 0 | Direct | |
| Aug 18, 2025 | Common Stock | MOption exerciseDisposed | −19,200 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale prices ranged from $13.30 to $14.80.
Referenced by the price of 1 transaction in Table I.
- F3
The sale prices ranged from $14.88 to $15.91.
Referenced by the price of 1 transaction in Table I.
- F4
The sale prices ranged from $15.61 to $16.00.
Referenced by the price of 1 transaction in Table I.